MedTrace Logo

Autologous Hematopoietic Stem Cell Transplantation for Crohn's Disease Treatment

NCT01932658 · Status: WITHDRAWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL

Last updated 2016-04-15

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and potential clinical benefit of lymphoablation followed by autologous HSCT rescue in therapy refractory Crohn's disease

Conditions

Interventions

BIOLOGICAL

Hematopoietic stem cell transplantation

Lymphoablation followed by hematopoietic stem cell transplantation to rescue the immune system.

Sponsors & Collaborators

Principal Investigators

  • Daniel W Hommes, MD,PhD · University of California, Los Angeles

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
7 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2016-03-31
Completion
2017-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01932658 on ClinicalTrials.gov